The aryl hydrocarbon receptor market has seen considerable growth due to a variety of factors.
• There has been substantial growth in the aryl hydrocarbon receptor market in previous years. The market expansion is expected to rise from $4.64 billion in 2024 to $5.01 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%.
The growth during the historical period can be attributed to several factors including increased understanding of environmental toxins, amplified research in the area of oncology, a surge in autoimmune disease research, a burgeoning interest in targeted therapies, and the widening use of applications in drug development.
The aryl hydrocarbon receptor market is expected to maintain its strong growth trajectory in upcoming years.
• Strong expansion is anticipated for the aryl hydrocarbon receptor market size over the upcoming years, with projections suggesting a rise to $6.79 billion in 2029 through a compound annual growth rate (CAGR) of 7.9%.
The growth in the projected time frame can be credited to an increase in funding for precision medicine, amplified demand for immunotherapy, an elevated attention towards environmental health, a surge in the use for inflammatory diseases, and escalating progress in the field of drug discovery. The period of forecast is anticipated to witness major trends such as advancements in targeted cancer therapies, adoption of precision medicine tactics, progression in toxicology research, the embrace of AI for drug discovery, and strides in treatment for autoimmune diseases.
The escalation of autoimmune diseases and persistent illnesses is anticipated to drive the growth of the aryl hydrocarbon receptor market in the future. These conditions involve long-term health problems or a malfunctioning immune system. Factors like genetics, environmental influences, lifestyle choices, gut imbalances, and improved diagnostic methods contribute to the rising prevalence of autoimmune diseases and chronic conditions. Aryl hydrocarbon receptor (AHR) agonists have the potential to regulate immune and inflammatory responses, thereby offering potential treatment benefits by controlling T-cell differentiation and immune cell function. For example, data from Public Health Scotland in July 2023 showed an increase in newly diagnosed multiple sclerosis (MS) patients to 87.2% in 2022, up from 85.7%, with 491 fresh cases reported, resulting in a total of 6,359 cases in 2022. Hence, the increasing trend in autoimmune diseases and long-term illnesses is contributing to the growth of the aryl hydrocarbon receptor (AHR) agonist market.
The aryl hydrocarbon receptor market covered in this report is segmented –
1) By Type: CB-993113, CDR-914K058, Cinnabarinic Acid, Other Types
2) By Distribution Channel: Direct Sales, Online Platforms, Distributors, Retail Pharmacies, Wholesale Suppliers
3) By Application: Hepatocellular Carcinoma, Multiple Sclerosis, Obesity, Osteoporosis, Other Applications
4) By End-User Industry: Pharmaceuticals, Biotechnology, Agriculture, Environmental Consultancy, Research Institutions
Subsegments:
1) By CB-993113: Preclinical Stage CB-993113, Clinical Trials of CB-993113, Targeted Applications of CB-993113
2) By CDR-914K058: Preclinical Development of CDR-914K058, CDR-914K058 in Immunological Disorders, Targeted Therapeutic Areas for CDR-914K058
3) By Cinnabarinic Acid: Mechanism Of Action Of Cinnabarinic Acid, Cinnabarinic Acid In Inflammatory Conditions, Potential Applications In Neurodegenerative Diseases
4) By Other Types: Synthetic Aryl Hydrocarbon Receptor Agonists, Natural Aryl Hydrocarbon Receptor Ligands, Novel Aryl Hydrocarbon Receptor Modulators
Key players in the aryl hydrocarbon receptor market are prioritizing the development of innovative products, such as specialized topical treatments, aimed at distinct inflammatory pathways. These novel treatments can provide potential solutions for various autoimmune ailments, including psoriasis and multiple sclerosis, as well as other persistent inflammatory conditions, while also minimizing side effects. Topical medications are drugs applied directly to the skin or mucous membranes to address local conditions or symptoms. For example, in May 2022, Dermavant Sciences, an American biopharmaceutical firm, was granted approval by the U.S. Food and Drug Administration (FDA) for 1% VTAMA (tapinarof) cream. This unique non-steroidal treatment provides new action mechanisms through its selective aryl hydrocarbon receptor modulation. The cream is designed for once-a-day application, making it a user-friendly choice for patients. Furthermore, its favorable safety track record and minimal systemic absorption set it apart from conventional treatments.
Major companies operating in the aryl hydrocarbon receptor market are:
• Bayer AG
• Eli Lilly and Company
• Organon & Co.
• Sigma-Aldrich Corporation
• Bio-Techne Corporation
• Abcam plc
• R&D Systems Inc.
• Dermavant Sciences Inc.
• Cayman Chemical Company
• Enzo Life Sciences Inc.
• Tocris Bioscience
• Ikena Oncology Inc.
• MedChemExpress LLC
• Hercules Pharmaceuticals BV
• Active Biotech AB
• AnTolRx Inc.
• Aqilion AB
• Azora Therapeutics Australia Pty Ltd
• Sol-Gel Technologies Ltd.
• Actavalon Inc.
North America was the largest region in the aryl hydrocarbon receptor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aryl hydrocarbon receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.